Skip to main content

Conjunctival Staining

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
2 programs
2.5/5.0/10.0 µL lissamine greenN/A1 trial
Complete Easy RubN/A1 trial
Active Trials
NCT00768898Completed30
NCT00799422Completed26Est. Mar 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AlconComplete Easy Rub
Alcon2.5/5.0/10.0 µL lissamine green

Clinical Trials (2)

Total enrollment: 56 patients across 2 trials

NCT00799422AlconComplete Easy Rub

Evaluation of Contact Lenses and Conjunctival Staining in Normal Patients

Start: Nov 2008Est. completion: Mar 200926 patients
N/ACompleted
NCT00768898Alcon2.5/5.0/10.0 µL lissamine green

Defining the Conjunctival Staining Method: Instillation Volume and Time Course to Assess Staining With Lissamine Green

Start: Aug 200830 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.